Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is verbatim operative text from 21 CFR 202.1(e)(6)(vi), which sits in the list of advertisements that ARE false, lacking in fair balance, or otherwise misleading. It is not an example, definition, or description of what is not required, so it does establish an affirmative disclosure obligation.
- Atomic: subparagraph (vi) bundles two prongs (concomitant therapy and placebo effect); the rule correctly isolates only the concomitant-therapy prong, which is a single checkable requirement. The placebo prong, with its own carve-out for non-human use, is properly left out.
- Determinism correctly set to 'judgment': whether claimed results 'may be due to' concomitant therapy, and whether the omission 'misrepresent[s] the effectiveness,' cannot be settled by presence/absence or literal match.
- Authority correctly set to 'binding': this is a codified FDA regulation, not guidance.
- Severity 'blocker' is defensible: (e)(6) is the per se list rendering the advertisement violative of section 502(n) of the act, not the softer 'may be' list at (e)(7).
- applies_when is under-scoped. 21 CFR 202.1(e) applies to advertisements for prescription drugs ('An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading...'). A bare 'promotional' tag would fire on OTC materials and on promotional labeling, neither of which this provision governs.
- Overstated in the check: the regulation conditions the violation on references that 'misrepresent the effectiveness of a drug by failure to disclose' the concomitant-therapy confound. The check instead triggers on whether 'cited studies involved concomitant therapy' at all, which captures protocol-mandated or background standard-of-care therapy balanced across arms that does not confound the efficacy claim. The escalation clause does not cure this because the item would already be flagged.
- Locator 21 CFR 202.1(e)(6)(vi) is exact and matches the quoted text.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the operative text of 21 CFR 202.1(e)(6)(vi), which sits under the heading 'Advertisements that are false, lacking in fair balance, or otherwise misleading' and states that a prescription drug advertisement IS false/misleading if it contains literature or study references that misrepresent effectiveness by failure to disclose that claimed results may be due to concomitant therapy. This is an operative prohibition, not an example, definition, or preamble discussion, so a disclosure obligation follows directly.
- Not overstated: the rule keeps the source's own qualifiers rather than absolutizing them — it is conditioned on the concomitant therapy plausibly accounting for the claimed results and on nondisclosure misrepresenting effectiveness, tracking 'misrepresent the effectiveness ... by failure to disclose that claimed results may be due to concomitant therapy'. It correctly confines itself to prescription drug advertising, which is the scope of (e)(6) ('An advertisement for a prescription drug is false ... if it'), and explicitly disclaims OTC advertising and non-advertising promotional labeling. 'Could plausibly account for' is a reasonable restatement of 'may be due to' and does not broaden the obligation.
- Atomic: paragraph (vi) contains two independent limbs (concomitant therapy and placebo effect, the latter with its own human-use carve-out). The rule takes only the concomitant-therapy limb and leaves the placebo limb out, so it is a single checkable requirement.
- Determinism correctly 'judgment': the trigger depends on whether the concomitant therapy could account for the claimed results and whether omission misrepresents effectiveness — an assessment of scientific plausibility and impression, not a literal match or mere presence/absence of a string.
- Authority correctly 'binding': 21 CFR 202.1 is a codified FDA regulation, and (e)(6) is framed in mandatory 'is false ... misleading' terms, not 'should' or 'recommends'.
- applies_when is justified: (e)(6) governs prescription drug advertisements without distinguishing professional from consumer audiences, so including both 'hcp' and 'consumer' is correct; the prescription-drug-only and advertising-only limits are carried in the rule statement itself. The FDA waiver proviso at the end of (e)(6) is a case-specific petition mechanism and does not need to be encoded.
- Severity 'blocker' is defensible: conduct falling within (e)(6) renders the advertisement false or misleading and violative of section 502(n) of the act, i.e., a misbranding exposure rather than a stylistic defect.
- Locator 21 CFR 202.1(e)(6)(vi) matches the quoted subparagraph exactly, and the escalation trigger (uncertainty about whether the concomitant therapy could account for the results) is the correct point at which reviewer judgment runs out.